News & Publication

The BiTE trial at UAB is testing 92Bio’s investigational NTB-928, a first-of-its-kind FRα-targeting T-cell engager designed to harness […]

92Bio Co-Founder & CEO Ben Buelow is featured in Partnology’s Biotech Leader Spotlight, sharing his journey from concept-to-clinic […]